MARKHAM, ON, Oct. 3, 2011 /PRNewswire/ - Cytochroma today announced the
appointment of Ms. Lily Lam to its Board of Directors. Ms. Lam
replaces Dr. Cynthia Lavoie of VG Partners (part of VenGrowth Private
Equity Partners Inc) and VenGrowth Advanced Life Sciences Fund Inc.
This appointment follows the acquisition of the Vengrowth Advanced Life
Sciences Fund Inc. by the Covington Fund II Inc.
"We are delighted to welcome Covington as a new investor in Cytochroma
and Lily Lam to the Board," said Dr. Alan J. Lewis, Chairman. "The
Company is poised to enter late stage development with a strong product
portfolio and will benefit from Lily's business and financial savvy.
We are grateful for Cynthia Lavoie's advice over the years, both on and
off the board, and wish her well."
Ms. Lam is Vice President, Investments at Covington Capital, having
joined the firm in November 2000. Her responsibilities include
assessing new business opportunities, negotiating and structuring
transactions and actively advising investee companies in a variety of
sectors including healthcare, media, software and service. Prior to
joining Covington, Lily held various research and management positions
within several early-stage healthcare companies where she provided
expertise in finance, operations and strategic direction. Lily holds an
MBA from York University with a specialization in Strategic Management.
She also holds a Master of Science from the Department of Immunology at
the University of Toronto.
Lily currently sits as a Director on the Boards of BTE Technologies
Inc., Interface Biologics Inc., Trillium Therapeutics Inc., Cytochroma
Inc., Zelos Therapeutics Inc. and Bedlam Games Inc. as well as holding
an observer position on the Boards of Adventus Remediation
Technologies, Neuraxon Inc., Natrix Separations Inc., iStopover Inc.,
and Affinium Pharmaceuticals Inc.
Cytochroma is a clinical stage specialty pharmaceutical company focused
on developing and commercializing proprietary products to treat and
prevent the clinical consequences of vitamin D insufficiency and
secondary hyperparathyroidism associated with chronic kidney disease
(CKD). The Company specializes in developing new therapies which are
designed to safely and effectively treat patients with stage 3, 4 or 5
CKD. Cytochroma also has a portfolio CYP24 and phosphate-uptake
inhibitors in early stage development.
For more information about Cytochroma, please visit www.cytochroma.com.